The biosimilar industry faces awareness challenges among health care professionals (HCPs), which must be addressed to ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

Real-world study reveals comparable effectiveness of bevacizumab biosimilars and Avastin in metastatic colorectal cancer (CRC ...

Number 5: FDA approvals for new biosimilars like Starjemza and Hadlima enhance treatment options, addressing urgent needs for ...

Patent settlements accelerate the entry of generics and biosimilars, saving the health care system $422.9 billion and ...

New research confirms denosumab biosimilar SB16 matches Prolia in efficacy, offering a cost-effective treatment option for ...

Denosumab biosimilars Wyost and Jubbonti launch in the US, enhancing access to affordable treatments for osteoporosis and ...

Biosimilar associations advocate for lower development costs and streamlined regulations to enhance patient access to ...